Phytanic Acid Oxidase Deficiency

Phytanic acid oxidase deficiency is a genetic problem in how the body breaks down a fatty substance called phytanic acid. Normally, an enzyme in peroxisomes (tiny cell parts) starts “alpha-oxidation” and safely clears phytanic acid. When this enzyme is missing or weak, phytanic acid builds up in blood and tissues. This slow buildup hurts nerves, eyes, skin, ears, and sometimes the heart. People may develop night blindness and retinitis pigmentosa, numbness and burning in feet and hands, balance and walking trouble (ataxia), loss of smell, scaly skin (ichthyosis), hearing loss, and irregular heart rhythms. Symptoms can appear in late childhood, teens, or adulthood and vary from person to person. The most proven treatment is strict, lifelong restriction of phytanic-acid-rich foods and, during flares, therapeutic plasma exchange to lower the level quickly. Early diagnosis, diet, and rehab help people stay active.

Phytanic acid cannot use the usual fat-burning route (β-oxidation) because it has a side-methyl “branch.” It must first undergo α-oxidation inside peroxisomes to become pristanic acid, which then can be further broken down. If the first step (done by phytanoyl-CoA hydroxylase) fails, phytanic acid accumulates and causes the typical problems. NCBIWikipedia

Phytanic acid is strictly from diet—humans do not make it from scratch. It mainly comes from fats of ruminant animals (like cows, sheep, goats) and dairy, and to a lesser extent certain fish. That is why diet can strongly influence symptoms in this condition. NCBIPMCScienceDirect

Other names

Phytanic acid oxidase deficiency has several other names used in medical writing. The most common is adult Refsum disease (ARD). Older names include heredopathia atactica polyneuritiformis (the original term used by Sigvald Refsum), phytanic acid α-oxidase deficiency, and phytanic acid storage disease. All of these names point to the same core problem: build-up (storage) of phytanic acid because the α-oxidation step—specifically the phytanoyl-CoA hydroxylase step—is not working. Some people also say “PHYH deficiency” to emphasize the gene involved. These names matter because medical articles and reports may use any of them, but they refer to the same disease process. WikipediaNCBI

Types

1) Classic/Adult Refsum disease (primary PHYH enzyme defect).
This is the main form. It is autosomal recessive, caused by harmful changes in the PHYH gene. More than 90% of people with adult Refsum disease have PHYH mutations. The enzyme is present in peroxisomes but does not work well enough, so phytanic acid accumulates. Onset is often in late childhood to early adulthood. NCBI

2) PEX7-related Refsum phenotype (peroxisomal import problem).
A smaller group has changes in PEX7, the receptor that helps bring some enzymes (including phytanoyl-CoA hydroxylase) into the peroxisome. Here, the enzyme may be normal in sequence but cannot get to the right place, so α-oxidation still fails and phytanic acid rises. This is sometimes called a “Refsum-like” presentation due to PEX7. NCBI

3) “Infantile Refsum disease” (Zellweger spectrum; related but distinct).
This is not the same disease as adult Refsum disease. It belongs to peroxisomal biogenesis disorders (Zellweger spectrum). Many peroxisome functions are impaired, not just α-oxidation. Phytanic acid can be high, but multiple other lab abnormalities also appear. Clinically it is more severe and appears in infancy. It is included here only to clarify the terminology because the names can be confusing. NCBI

Causes

1) Biallelic PHYH mutations (autosomal recessive).
The most common direct cause. Two non-working copies of PHYH prevent the first α-oxidation step, so phytanic acid accumulates. Parents are usually healthy carriers. NCBI

2) PEX7 mutations impairing peroxisomal import.
Defective PEX7 blocks import of PHYH (and other PTS2-tagged proteins) into peroxisomes, leading to phytanic acid build-up. NCBI

3) Compound heterozygosity within PHYH.
Two different harmful PHYH variants—one from each parent—can combine to cause disease, even if each variant alone is rare. NCBI

4) Founder variants in certain populations.
In some regions/families, specific PHYH or PEX7 variants occur more often, increasing disease likelihood within that group. NCBI

5) Consanguinity (parents related by blood).
Raises the chance that both parents carry the same rare PHYH or PEX7 variant, increasing the autosomal-recessive risk. NCBI

6) Peroxisomal enzyme mis-targeting.
Even with a normal PHYH protein sequence, failure of peroxisomal targeting (e.g., PTS2 pathway issues) can cause functional deficiency. NCBI

7) Diet very high in phytanic acid.
Heavy intake of ruminant fats, dairy, or certain fish raises phytanic acid load and can unmask or worsen disease in genetically affected people. PMC

8) Rapid weight loss or prolonged fasting.
Stored phytanic acid is released from fat during lipolysis, acutely boosting blood levels and symptoms. NCBI

9) Acute illness or catabolic stress.
Fever, infection, or surgery can increase fat breakdown and raise circulating phytanic acid in affected individuals. NCBI

10) Pregnancy (rare trigger).
Physiologic shifts in lipid metabolism may change phytanic acid handling; careful dietary control is important. (Inference consistent with catabolic-state cautions.) NCBI

11) Reduced renal function.
Kidney impairment may slow clearance of fatty acid metabolites, potentially raising levels in those with the enzyme defect. (Inference; management focuses on minimizing load.) NCBI

12) Liver dysfunction.
Peroxisomes are plentiful in liver; broader liver disease can aggravate metabolic handling of phytanic/pristanic acids. (Inference aligned with peroxisomal metabolism.) NCBI

13) Errors in companion α-oxidation enzymes.
Although rare, defects that affect other α-oxidation components (e.g., HACL1 pathway context) can influence handling of branched-chain fatty acids. PMCPortland Press

14) Thiamine deficiency reducing HACL1 activity.
Severe lack of thiamine can depress HACL1, an α-oxidation enzyme, and may worsen branched-fat processing. ScienceDirect

15) AMACR deficiency (differential, can elevate phytanic acid).
While not Refsum disease, AMACR defects can alter pristanic/bile acid metabolism and sometimes raise phytanic acid; they are an important look-alike cause to exclude. NCBI

16) Peroxisomal biogenesis disorders (Zellweger spectrum).
These broader disorders disrupt many peroxisomal functions and can cause high phytanic acid along with other abnormalities. NCBI

17) Inadequate dietary counseling in known patients.
Lack of guidance leads to avoidable high intake; education is key to prevent spikes. NCBI

18) Poor adherence to low-phytanic-acid diet.
Even with normal days, occasional high-phytanic meals can trigger worsening neuropathy or vision issues over time. NCBI

19) Limited access to specialized testing.
Delayed diagnosis means ongoing exposure and accumulation, which clinically “causes” progression. (Systems factor but clinically relevant.) NCBI

20) Lack of family screening and genetic counseling.
Unrecognized siblings or relatives may continue typical diets for years, allowing silent accumulation and symptom onset. NCBI

Symptoms

1) Night blindness and progressive vision loss.
Due to retinitis pigmentosa; many people first notice trouble seeing in the dark and shrinking side vision. NCBI

2) Loss of smell (anosmia).
A very common early sign; people often cannot smell everyday odors. NCBI

3) Cataracts and small pupils (miosis).
Clouding of the lens and pupil changes add to visual problems over time. NCBI

4) Peripheral neuropathy.
Numbness, tingling, burning pain, and weakness in feet and hands from nerve damage. NCBI

5) Ataxia (poor balance and coordination).
Damage to nerves/cerebellum makes walking unsteady; tandem walking is hard. NCBI

6) Reduced or absent reflexes.
Deep tendon reflexes may fade in a “length-dependent” pattern as neuropathy advances. NCBI

7) Hearing loss (sensorineural).
Gradual reduction in hearing sensitivity over years. NCBI

8) Dry, scaly skin (ichthyosis).
Typical skin finding that may improve with good control of phytanic acid. NCBI

9) Shortened fingers or toes (metacarpal/metatarsal shortening).
Some people have congenital bone changes noticed on exam or x-ray. NCBI

10) Heart rhythm problems.
Conduction abnormalities can cause palpitations, dizziness, or fainting. NCBI

11) Cardiomyopathy.
The heart muscle can weaken; breathlessness or swelling can appear in advanced cases. NCBI

12) Eye surface and iris changes.
Iris atrophy and other ocular features may be reported with disease progression. NCBI

13) Muscle weakness and fatigue.
From neuropathy and deconditioning; improved by stabilizing phytanic acid and physical therapy. NCBI

14) Slow, stepwise progression over years.
Symptoms often expand from eyes and smell to nerves, skin, and heart with time if untreated. NCBI

15) Acute worsening during stress, fasting, or crash diets.
Sudden rises in phytanic acid can trigger fast deterioration in vision and neuropathy; avoiding fasting helps. NCBI

Diagnostic tests

A) Physical examination

1) General neurologic exam.
Checks strength, sensation, coordination, and reflexes. Loss of ankle reflexes, distal weakness, and sensory loss suggest peripheral neuropathy typical of this disease. NCBI

2) Gait and balance assessment.
Simple walking, heel-to-toe (tandem) gait, and Romberg stance show ataxia and sensory imbalance seen in Refsum disease. NCBI

3) Skin examination.
Looks for ichthyosis (dry, scaly skin) that often accompanies phytanic acid build-up; improvement with control supports the diagnosis. NCBI

4) Musculoskeletal inspection of hands and feet.
Shortened metacarpals/metatarsals may be visible; further confirmed by x-ray. NCBI

5) Cardiovascular exam.
Pulse, blood pressure, and heart sounds may hint at arrhythmias or cardiomyopathy; triggers further testing. NCBI

B) Manual/bedside tests

6) Fundoscopic (ophthalmoscope) eye exam.
A doctor looks at the retina for retinitis pigmentosa changes—bone-spicule pigment, vessel narrowing, and pale optic disc—highly suggestive in this setting. NCBI

7) Visual field testing at the bedside.
Simple confrontation fields detect peripheral field loss; formal perimetry later quantifies damage. NCBI

8) Smell identification test (e.g., scratch-and-sniff).
Bedside screening or formal olfactory tests show anosmia, a very early clue. NCBI

9) Bedside coordination tests.
Finger-to-nose and heel-to-shin reveal cerebellar and sensory ataxia consistent with neuropathy/ataxia. NCBI

10) Tuning fork and bedside hearing checks.
Weber/Rinne and whispered voice tests screen for sensorineural hearing loss; formal audiometry follows. NCBI

C) Laboratory and pathological tests

11) Plasma phytanic acid level (key test).
Pathognomonic when clearly elevated; >30 µmol/L is abnormal and >200 µmol/L is typical in Refsum disease. Levels can vary with diet, so history matters. NCBI

12) Pristanic acid level.
Usually low or normal in classic Refsum disease, which helps separate it from other peroxisomal or AMACR disorders that raise pristanic acid. NCBI

13) Very-long-chain fatty acids (VLCFA) and bile acid intermediates.
These are typically normal in adult Refsum disease but abnormal in Zellweger spectrum disorders; this helps exclude peroxisomal biogenesis defects. NCBI

14) Genetic testing for PHYH and PEX7.
Confirms the cause and guides family counseling and carrier testing. NCBI

15) Fibroblast/peroxisomal enzyme studies.
Skin biopsy-based tests can show deficient α-oxidation of phytanic acid and support the diagnosis when genetics are unclear. NCBI

16) Specialized metabolites of α-oxidation.
In selected labs, measuring intermediates like 2-hydroxyphytanic acid can help characterize α-oxidation problems in related disorders. PubMed

D) Electrodiagnostic and cardiac tests

17) Nerve conduction studies and EMG.
Show a length-dependent sensorimotor polyneuropathy—reduced amplitudes and/or slowed conduction—matching symptoms. NCBI

18) Electroretinogram (ERG).
Measures retinal electrical responses; reduced signals are typical of retinitis pigmentosa in this disease. NCBI

19) Electrocardiogram (ECG).
Screens for conduction abnormalities (e.g., AV block) that may occur and can be serious if missed. NCBI

20) Echocardiogram (and Holter if needed).
Assesses cardiomyopathy and rhythm stability; essential if symptoms or ECG changes are present. NCBI

Non-pharmacological treatments

Physiotherapy

1. Gait and balance training
   Purpose: Reduce falls.
   Mechanism: Rehearses safe stepping, turning, and obstacle work; improves cerebellar compensation.
   Benefits: Smoother walking, fewer stumbles, more confidence.

2. Vestibular rehab
   Purpose: Ease dizziness and unsteadiness.
   Mechanism: Head-eye coordination drills recalibrate balance systems.
   Benefits: Better stability in crowds and dim light.

3. Strength training (lower limbs and core)
   Purpose: Support weak ankles/knees and trunk.
   Mechanism: Progressive resistance (bands/weights) grows muscle fibers and motor control.
   Benefits: Stronger push-off, improved endurance, safer stairs.

4. Task-specific endurance walking
   Purpose: Increase distance without fatigue.
   Mechanism: Interval walking raises aerobic capacity and nerve efficiency.
   Benefits: Longer community ambulation, less shortness of breath.

5. Ankle–foot orthoses (AFO) assessment + training
   Purpose: Correct foot drop and foot-slap from neuropathy.
   Mechanism: Bracing positions ankle for a stable heel strike.
   Benefits: Safer, more energy-efficient gait.

6. Stretching for calves, hamstrings, hip flexors
   Purpose: Prevent contractures and pain.
   Mechanism: Slow holds remodel tight tissue, preserving range.
   Benefits: Easier walking, less cramping, better posture.

7. Proprioceptive and sensory re-education
   Purpose: Improve joint position sense with numb feet.
   Mechanism: Textured surfaces, eyes-closed drills heighten remaining pathways.
   Benefits: More secure stepping without over-reliance on vision.

8. Functional electrical stimulation (FES) for foot drop
   Purpose: Lift toes in swing phase.
   Mechanism: Timed peroneal-nerve stimulation activates dorsiflexors.
   Benefits: Fewer trips, more natural stride.

9. Hand therapy for fine motor skills
   Purpose: Help buttons, pens, phones.
   Mechanism: Dexterity drills strengthen intrinsic hand muscles.
   Benefits: Independent dressing and writing.

10. Postural control and trunk stability
    Purpose: Reduce sway and back fatigue.
    Mechanism: Core activation (planks, bridges) improves anticipatory balance.
    Benefits: Safer reaching and carrying.

11. Energy conservation coaching
    Purpose: Manage fatigue.
    Mechanism: Pacing, task clustering, sit-to-work strategies.
    Benefits: More activity spread through the day.

12. Fall-prevention home program
    Purpose: Cut injury risk.
    Mechanism: Practice sit-to-stand, dual-task walking, safe turning; remove hazards.
    Benefits: Fewer falls, more independence.

13. Breathing and chest mobility (if deconditioned)
    Purpose: Improve stamina.
    Mechanism: Diaphragmatic breathing and thoracic mobility increase tidal volume.
    Benefits: Better exercise tolerance.

14. Heat/cold modalities for neuropathic discomfort
    Purpose: Ease burning/aching.
    Mechanism: Thermal input modulates pain signaling.
    Benefits: Short-term relief; better exercise tolerance.

15. Aquatic therapy
    Purpose: Train safely with poor balance.
    Mechanism: Buoyancy lowers joint load; water resistance builds strength.
    Benefits: Confidence, cardio fitness, and fewer falls.

Mind-Body / Gene-informed supports

16. Sleep hygiene program
    Purpose: Cut pain sensitivity and fatigue.
    Mechanism: Regular schedule, dark/cool room, no late caffeine stabilizes circadian rhythm.
    Benefits: More energy, steadier mood, better rehab gains.

17. Mindfulness-based stress reduction
    Purpose: Lower pain distress and anxiety.
    Mechanism: Attention training reduces limbic amplification of pain signals.
    Benefits: Improved coping and adherence to diet.

18. Nutritional counseling for phytanic-acid restriction
    Purpose: Keep levels low for life.
    Mechanism: Swap ruminant fats/dairy for plant and MCT fats; plan safe proteins.
    Benefits: Fewer flares, steadier nerves and skin.

19. Genetic counseling for family planning
    Purpose: Understand inheritance (autosomal recessive).
    Mechanism: Carrier testing and options discussion.
    Benefits: Informed decisions; early screening in relatives.

20. Future-focused education on gene therapy (info only)
    Purpose: Know what is experimental.
    Mechanism: Learn about AAV/mRNA/editing research, not standard care.
    Benefits: Realistic expectations; trial awareness.

Educational / Practical therapies

21. Low-vision rehabilitation
    Purpose: Work around night blindness and field loss.
    Mechanism: Contrast, task lighting, magnification, mobility skills.
    Benefits: Safer navigation, reading, daily living.

22. Hearing rehabilitation
    Purpose: Improve communication.
    Mechanism: Hearing aids, assistive devices, lip-reading training.
    Benefits: Less isolation and fatigue.

23. Skin care program for ichthyosis
    Purpose: Reduce scaling and itch.
    Mechanism: Daily lukewarm soaks, bland emollients, gentle keratolytic routine as advised.
    Benefits: Softer skin, fewer cracks/infections.

24. Cardiac safety education
    Purpose: Prevent arrhythmia harms.
    Mechanism: Recognize palpitations/syncope, avoid crash dieting, keep electrolytes balanced.
    Benefits: Lower risk of dangerous events.

25. Work/school accommodations
    Purpose: Match tasks to ability.
    Mechanism: Seating near light, extra breaks, reduced night travel, written instructions.
    Benefits: Better performance with less strain.

Drug treatments

1. Gabapentin (antineuropathic; 100–3,600 mg/day in divided doses)
   Purpose: Nerve pain. Mechanism: Calms overactive pain neurons (α2δ calcium channels).
   Side effects: Sleepiness, dizziness, swelling.

2. Pregabalin (antineuropathic; 75–600 mg/day)
   Similar to gabapentin; faster onset. Side effects: Dizziness, weight gain, edema.

3. Duloxetine (SNRI; 30–120 mg/day)
   Purpose: Neuropathic pain and mood. Mechanism: Boosts serotonin/norepinephrine pain control pathways.
   Side effects: Nausea, dry mouth, sleep changes.

4. Amitriptyline (TCA; 10–75 mg at night)
   Purpose: Nerve pain/sleep. Mechanism: Serotonin/norepinephrine reuptake block; anticholinergic.
   Side effects: Dry mouth, constipation, next-day grogginess.

5. Baclofen (antispastic; 5–80 mg/day)
   Purpose: Muscle stiffness/spasms. Mechanism: GABA-B agonist reduces reflex hyperactivity.
   Side effects: Drowsiness, weakness.

6. Tizanidine (antispastic; 2–36 mg/day)
   Purpose: Spasm relief. Mechanism: α2-agonist dampens spinal motor output.
   Side effects: Low blood pressure, sedation.

7. Metoprolol or Propranolol (beta-blockers; dose per cardiology)
   Purpose: Control tachyarrhythmias/palpitations. Mechanism: Slows heart rate, reduces ectopy.
   Side effects: Fatigue, low BP; asthma caution (propranolol).

8. Mexiletine (antiarrhythmic; 200–600 mg/day)
   Purpose: Selected ventricular arrhythmias or neuropathic pain off-label.
   Mechanism: Sodium-channel block. Side effects: GI upset, tremor; cardiology supervision needed.

9. Acetazolamide (carbonic anhydrase inhibitor; 250–1,000 mg/day)
   Purpose: Sometimes eases episodic ataxia symptoms.
   Mechanism: Alters neuronal pH/excitability. Side effects: Tingling, kidney stone risk.

10. Topical urea 10–20% creams/lotions (OTC/Rx)
    Purpose: Ichthyosis scaling. Mechanism: Humectant/keratolytic softens stratum corneum.
    Side effects: Mild sting on broken skin.

11. Topical salicylic acid 3–6% (derm-advised)
    Purpose: Thicker plaques. Mechanism: Keratolysis breaks down scale.
    Side effects: Irritation; avoid large areas in children.

12. Artificial tears / ocular lubricants (as needed)
    Purpose: Dry eye from reduced blink or exposure.
    Mechanism: Replaces tear film; protects cornea. Side effects: Rare irritation.

13. Melatonin 1–5 mg at bedtime
    Purpose: Sleep onset issues. Mechanism: Circadian cue. Side effects: Morning grogginess in some.

14. Magnesium glycinate 200–400 mg at night (if appropriate)
    Purpose: Cramps, sleep quality. Mechanism: Neuromuscular calming. Side effects: Loose stools if overdosed.

15. Levocarnitine (ONLY if your specialist prescribes; typical 50–100 mg/kg/day)
    Purpose: Address secondary carnitine depletion.
    Mechanism: Shuttles fatty acids; may aid acyl removal. Caution: Can raise certain acylcarnitines—must be monitored.

Note: There is no proven pill that directly fixes the enzyme defect or reliably clears phytanic acid. The cornerstone is diet; plasma exchange is a procedure (see below) used for rapid lowering during flares.

Dietary molecular supplements

1. Vitamin E (200–400 IU/day) – Antioxidant; may protect nerves/retina from oxidative stress; helps membrane stability.

2. Vitamin C (250–500 mg/day) – Regenerates vitamin E; supports collagen/skin healing; antioxidant synergy.

3. Alpha-lipoic acid (300–600 mg/day) – Antioxidant used in neuropathy; improves nerve glucose handling and redox balance.

4. Coenzyme Q10 (100–200 mg/day) – Supports mitochondrial ATP; may aid fatigue and muscle endurance.

5. B-complex with B1, B6, B12 (daily) – Supports nerve repair and neurotransmitters; corrects hidden deficiencies.

6. Vitamin D3 (per level, often 1,000–2,000 IU/day) – Bone/immune support; low levels worsen muscle and fall risk.

7. Magnesium (200–400 mg/day) – Neuromuscular calming, sleep support; choose gentle salts to avoid diarrhea.

8. N-acetylcysteine (600–1,200 mg/day) – Glutathione precursor; antioxidant for nerve/skin stress.

9. Plant-based omega-3 (ALA from flax/chia; or algal DHA per label) – Anti-inflammatory lipids without fish-oil phytanic acid risk.

10. MCT oil (start 1 tsp with meals, titrate) – Calorie source that does not carry phytanic acid and is burned quickly; helps maintain weight while on low-fat/low-phytanic diet.

Immunity booster / regenerative / stem-cell

1. Up-to-date vaccinations – Reduces infection stress that can worsen weakness and fatigue; evidence-based immune protection.

2. mRNA therapy concepts (research) – Deliver working enzyme instructions; still pre-clinical/early-phase for this disease.

3. AAV-based gene transfer (research) – Aim: supply a functional PHYH gene to liver or target tissues; safety/efficacy not yet established.

4. Ex vivo gene-edited hematopoietic stem cells (research) – Theoretically provide long-term enzyme source; currently experimental only.

5. Mesenchymal stromal cells for neuropathy (research) – Proposed anti-inflammatory/neurotrophic effects; no proven benefit here yet.

6. Targeted small-molecule chaperones (research) – Stabilize misfolded enzyme variants; concept stage in peroxisomal disorders.

Bottom line: Consider clinical trials only with expert centers; avoid unregulated “stem cell clinics.”

Procedures / surgeries

1. Therapeutic plasma exchange (plasmapheresis)
   What: Removes phytanic-acid-rich plasma and replaces with donor fluid/albumin.
   Why: Rapidly lowers levels during acute flare (worsening neuropathy, arrhythmia, severe skin disease).

2. Lipid apheresis (where available)
   What: Filters lipoproteins that carry phytanic acid.
   Why: Alternative rapid reduction when expertise/equipment exist.

3. Cochlear implant (for severe hearing loss not helped by aids)
   What: Internal electrode stimulates auditory nerve.
   Why: Restores sound perception and communication.

4. Cataract surgery (if visually significant cataract coexists)
   What: Clouded lens removal with clear implant.
   Why: Improves visual clarity alongside low-vision rehab.

5. Pacemaker/ICD (cardiology-guided)
   What: Device to correct dangerous slow/fast rhythms.
   Why: Prevents syncope or sudden cardiac events when arrhythmias are documented.

Preventions

1. Lifelong low-phytanic-acid diet.

2. Avoid fasting and crash dieting (fat breakdown releases phytanic acid).

3. Maintain steady weight with safe calories (e.g., MCTs, plant foods).

4. Read labels for hidden dairy fats, ghee, tallow.

5. Prefer poultry/plant proteins; avoid ruminant meats (beef, lamb, mutton) and high-risk ocean fish.

6. Limit alcohol, which worsens neuropathy and heart rhythm.

7. Treat infections promptly; illness can trigger setbacks.

8. Keep electrolytes normal (hydration, magnesium, potassium) to protect heart rhythm.

9. Routine follow-up: check plasma phytanic acid, nerves, skin, vision, hearing, and ECG.

10. Family screening/genetic counseling to identify at-risk relatives early.

What to eat and what to avoid

1. Avoid: Beef, lamb, mutton, goat fat/offal.

2. Avoid: Full-fat dairy—whole milk, cream, butter, ghee, hard cheeses.

3. Avoid: Certain ocean fish known to be high in phytanic acid (ask your clinic for the local “avoid list”).

4. Prefer: Poultry and plant proteins (beans, lentils, tofu, tempeh).

5. Prefer: Skim/very low-fat dairy if your specialist allows (phytanic acid sits in fat).

6. Use: Plant oils (olive, canola) and MCT oil for calories.

7. Fill half the plate with fruits and vegetables.

8. Choose whole grains for steady energy.

9. Plan snacks to avoid long fasting gaps.

10. Work with a dietitian to personalize safe menus and keep weight stable.

When to see a doctor urgently

• New or fast-worsening vision changes, severe night blindness, or visual field loss.

• Palpitations, fainting, chest pain, or shortness of breath.

• Rapidly worsening numbness, weakness, balance, or sudden falls.

• Severe dehydration, vomiting, or inability to keep diet—risk of catabolism.

• Skin infections from cracks or ulcers.

• Fever or other infection signs.

• Pregnancy planning or if you are pregnant—diet and monitoring need updates.

Frequently asked questions

1. Is it inherited? Yes, autosomal recessive. Both parents are usually carriers.

2. Is there a cure? No cure yet. Diet plus supportive care control it.

3. Why is diet so important? Phytanic acid comes mainly from foods; less in means lower blood levels.

4. Why avoid fasting? Breaking down body fat releases stored phytanic acid.

5. Can I eat fish oil? Avoid standard fish oils; ask about algal omega-3 instead.

6. Will vision always get worse? Vision varies. Low-vision rehab helps function, but retinitis pigmentosa is usually progressive.

7. Can nerves recover? Some symptoms improve when levels fall, but damaged nerves may recover slowly or partly.

8. What labs are tracked? Plasma phytanic acid (and sometimes pristanic acid), liver profile, electrolytes; ECG for heart rhythm.

9. Are children affected? Yes if they inherit two faulty genes; early diet and monitoring help.

10. Is pregnancy safe? Needs specialist planning to avoid catabolism and manage nutrition.

11. What about exercise? Regular, paced exercise is good; avoid extreme fasting or overexertion that causes big weight loss.

12. Any new treatments coming? Research is exploring gene and RNA strategies; not clinical standard yet.

13. Do I need vitamin A? Do not take high-dose vitamin A; follow ophthalmologist advice.

14. Can hearing improve? Hearing aids or implants can help communication even if nerve damage remains.

15. How often are checkups? Typically every 3–6 months at first, then individualized based on stability.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 09, 2025.